US Edition
Zealand Pharma submits glepaglutide MAA for short bowel syndrome
Summary by Pharmaceutical Business Review
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Zealand Pharma submits glepaglutide MAA for short bowel syndrome
Glepaglutide is intended for administering two times a week for SBS. The application is based on results from the pivotal Phase III clinical trial EASE-1, supported by interim The post Zealand Pharma submits glepaglutide MAA for short bowel syndrome appeared first on Pharmaceutical Business review.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
